ORMP
vs
S&P 500
ORMP
S&P 500
Over the past 12 months, ORMP has outperformed S&P 500, delivering a return of +28% compared to the S&P 500's +12% growth.
Stocks Performance
ORMP vs S&P 500
Performance Gap
ORMP vs S&P 500
Performance By Year
ORMP vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Oramed Pharmaceuticals Inc
Glance View
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The firm has three product pipelines: ORMD-0801 type 2, ORMD-0801 type 1 and ORMD-0901. ORMD-0801 allows insulin to travel from the gastrointestinal tract via the portal vein to the bloodstream, where the insulin is delivered. The company is in Phase III of clinical trials. ORMD-0901 (GLP-1 capsule), aids in the balance of blood-sugar levels and decreases appetite. The firm is also engaged in the research and development of an oral vaccine for COVID-19 through its subsidiary Oravax Medical Inc., or Oravax.